Hims & Hers Stock: Profitability Concerns Overshadow Strong Revenue Growth

The telehealth sector once represented one of the market’s most promising growth stories, but recent results from Hims & Hers Health reveal significant challenges beneath the surface. While the company continues to demonstrate impressive revenue expansion, its latest quarterly report highlights substantial profitability issues that have shaken investor confidence.

Analyst Sentiment Turns Cautious

Market reaction to the November 3rd earnings release was swift and severe, with shares declining 7.6% following the announcement. Financial analysts at Wall Street Zen have downgraded the stock to a “Sell” rating, indicating limited optimism about near-term recovery. Their average price target sits at $45.27, representing minimal upside from current trading levels.

The company faces additional headwinds beyond its financial metrics. Regulatory pressure emerged in September when the FDA issued a warning regarding potentially misleading advertising for weight loss supplements. Management has further tempered expectations by guiding toward narrower revenue margins for the full year.

Record Revenue Masks Underlying Weakness

Hims & Hers delivered seemingly robust third-quarter 2025 results with revenue surging 49% to reach $599 million, comfortably exceeding market expectations. However, this impressive top-line performance concealed troubling developments elsewhere in the financial statement.

Should investors sell immediately? Or is it worth buying Hims & Hers?

Earnings per share contracted sharply by 40%, significantly missing analyst forecasts. More alarmingly, the company’s gross margin compressed from 79% to 74%, indicating rising costs within its core operations. Even with a subscriber base exceeding 2.4 million members and growing average revenue per customer, these fundamental profitability challenges proved impossible to ignore.

Strategic Initiatives Face Market Challenges

In response to these pressures, Hims & Hers is pursuing several strategic initiatives aimed at diversifying its business model. The company has launched “Labs,” an extensive testing service, and is reportedly in discussions with Novo Nordisk regarding a potential partnership in the weight management medication space.

Despite these efforts, the path forward appears challenging. The telehealth industry faces increasing competitive pressures while regulatory scrutiny continues to intensify. The central question for investors remains whether Hims & Hers can successfully convert its rapid revenue expansion into sustainable profitability.

The company’s next quarterly report scheduled for February 2026 will provide critical insight into whether recent stock performance represents a temporary setback or the beginning of a more prolonged downward trend.